Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Other Accumulated Expenses: 2015-2023

Historic Other Accumulated Expenses for Editas Medicine (EDIT) over the last 7 years, with Jun 2023 value amounting to $78,000.

  • Editas Medicine's Other Accumulated Expenses fell 97.18% to $78,000 in Q2 2023 from the same period last year, while for Jun 2023 it was $78,000, marking a year-over-year decrease of 97.18%. This contributed to the annual value of $1.6 million for FY2022, which is 16.12% up from last year.
  • Latest data reveals that Editas Medicine reported Other Accumulated Expenses of $78,000 as of Q2 2023, which was down 28.44% from $109,000 recorded in Q1 2023.
  • Editas Medicine's 5-year Other Accumulated Expenses high stood at $4.0 million for Q2 2020, and its period low was $78,000 during Q2 2023.
  • Moreover, its 3-year median value for Other Accumulated Expenses was $657,500 (2021), whereas its average is $878,500.
  • In the last 5 years, Editas Medicine's Other Accumulated Expenses surged by 289.84% in 2020 and then slumped by 97.18% in 2023.
  • Over the past 5 years, Editas Medicine's Other Accumulated Expenses (Quarterly) stood at $2.7 million in 2019, then tumbled by 57.87% to $1.1 million in 2020, then grew by 24.60% to $1.4 million in 2021, then climbed by 16.12% to $1.6 million in 2022, then tumbled by 97.18% to $78,000 in 2023.
  • Its Other Accumulated Expenses stands at $78,000 for Q2 2023, versus $109,000 for Q1 2023 and $1.6 million for Q4 2022.